Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis

Clinical Cardiology

Volumn 38, Issue 2, 2015, Pages 69-75

  Cappelli, Francesco ^a,b,c   Baldasseroni, Samuele ^a   Bergesio, Franco ^b   Perlini, Stefano ^c   Salinaro, Francesco ^c   Padeletti, Luigi ^d   Attanà, Paola ^d   Paoletti Perini, Alessandro ^d   Pignone, Alberto Moggi ^c   Grifoni, Elisa ^c   Fabbri, Alessia ^c   Marchionni, Niccolò ^c   Gensini, Gian Franco ^d   Perfetto, Federico ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; PREALBUMIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; IMMUNOGLOBULIN LIGHT CHAIN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TROPONIN I;

AGED; AMYLOIDOSIS; ARTICLE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE WALL; HUMAN; HYPOTHESIS; LIGHT CHAIN; LIGHT CHAIN AMYLOIDOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; NEW YORK HEART ASSOCIATION CLASS; TRANSTHYRETIN AMYLOIDOSIS; AMYLOID NEUROPATHIES, FAMILIAL; BLOOD; CARDIOMYOPATHIES; COMPARATIVE STUDY; COMPLICATION; CROSS-SECTIONAL STUDY; DISEASE COURSE; DOPPLER ECHOCARDIOGRAPHY; ECHOGRAPHY; GENETICS; HEART LEFT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE FUNCTION; IMMUNOLOGY; MIDDLE AGED; MUTATION; PATHOPHYSIOLOGY; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMYLOID NEUROPATHIES, FAMILIAL; AMYLOIDOSIS; BIOMARKERS; CARDIOMYOPATHIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MIDDLE AGED; MUTATION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREALBUMIN; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TROPONIN I; VENTRICULAR FUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT;

EID: 84925384921     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22353     Document Type: Article

References (32)

1. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583-596.
2. Perfetto F, Cappelli F, Bergesio F, et al. Cardiac amyloidosis: the heart of the matter. Intern Emerg Med. 2013;8:191-203.
3. Smorti M, Cappelli F, Guarnieri S, et al. Depression and cardiac symptoms among AL amyloidosis patients: the mediating role of coping strategies. Psychol Health Med. 2014;19:263-272.
4. Smorti M, Cappelli F, Bergesio F, et al. Anxiety and depression among AL amyloidosis patients: the role of cardiac symptoms. Amyloid. 2012;19:123-128.
5. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120:1203-1212.
6. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation. 2003;107:2446-2452.
7. Porciani MC, Lilli A, Perfetto F, et al. Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis. Amyloid. 2009;16:63-70.
8. Porciani MC, Cappelli F, Perfetto F, et al. Rotational mechanics of the left ventricle in AL amyloidosis. Echocardiography. 2010;27:1061-1068.
9. Bellavia D, Pellikka PA, Dispenzieri A, et al. Comparison of right ventricular longitudinal strain imaging, tricuspid annular plane systolic excursion, and cardiac biomarkers for early diagnosis of cardiac involvement and risk stratification in primary systematic (AL) amyloidosis: a 5-year cohort study. Eur Heart J Cardiovasc Imaging. 2012;13:680-689.
10. Cappelli F, Porciani MC, Bergesio F, et al. Right ventricular function in AL amyloidosis: characteristics and prognostic implication. Eur Heart J Cardiovasc Imaging. 2012;13:416-422.
11. Liu D, Niemann M, Hu K, et al. Echocardiographic evaluation of systolic and diastolic function in patients with cardiac amyloidosis. Am J Cardiol. 2011;108:591-598.
12. Rapezzi C, Quarta CC, Riva L, et al. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7:398-408.
13. Sattianayagam PT, Hahn AF, Whelan CJ, et al. Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J 2012;33:1120-1127.
14. Ranlov I, Alves IL, Ranlov PJ, et al. A Danish kindred with familial amyloid cardiomyopathy revisited: identification of a mutant transthyretin-methionine111 variant in serum from patients and carriers. Am J Med. 1992;93:3-8.
15. Buxbaum J, Alexander A, Koziol J, et al. Significance of the Amyloidogenic Transthyretin Val 122 Ile allele in African-Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. Am Heart J. 2010;159:864-870.
16. Rapezzi C, Quarta CC,Obici L, et al.Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart J. 2013;34:520-528.
17. Dubrey S, Cha K, Skinner M, et al. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart. 1997;78:74-82.
18. Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chainassociated amyloidosis. Arch Intern Med. 2005;165:1425-1429.
19. Ogiwara F, Koyama J, Ikeda S, et al. Comparison of the strain Doppler echocardiographic features of familial amyloid polyneuropathy (FAP) and light-chain amyloidosis. Am J Cardiol. 2005;95:538-540.
20. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46:1076-1084.
21. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med . 1999;130:461-470.
22. Gertz, MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis. Am J Hematol. 2005;79:319-328
23. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440-1463.
24. Tei C, Ling LH, Hodge DO, et al. New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function: a study in normals and dilated cardiomyopathy. J Cardiol. 1995;26:357-366.
25. Ganau A, Devereux RB, Roman MJ, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992;19:1550-1558.
26. Quarta CC, Solomon SD, Uraizee I, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014;129:1840-1849.
27. Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004;94:1008-1010.
28. Perlini S, Palladini G, Vezzoli M. Reduction of circulating amyloidogenic light chains improves myocardial function and survival despite unaltered amount of amyloid myocardial deposits. Circulation. 2004;110(suppl 3):602.
29. Migrino RQ, Truran S, Gutterman DD, et al. Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. Am J Physiol Heart Circ Physiol. 2011;301:H2305-H2312.
30. Fontana M, Banypersad SM, Treibel TA, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7:157-165.
31. Hutt DF, Quigley AM, Page J, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014;15:1289-1298.
32. Perfetto F, Cappelli F, Bergesio F. Asymptomatic homozygous gene carrier in a family with Ile68Leu ATTR amyloidosis: a new endemic region in northern Tuscany? J Cardiovasc Med (Hagerstown). 2011;12:450-451.